To determine the benefits of prophylactic tranexamic acid administration in preventing the decline of postoperative hemoglobin levels, minimizing intraoperative blood loss, and reducing the necessity for blood transfusions. Decreased intraoperative bleeding enhances surgical field visualization, thereby improving surgical safety, minimizing the destruction of healthy ovarian tissue, and reducing the utilization of electrosurgical coagulation. Consequently, this limits thermal injury to the adjac
Conditions
Interventions
The experimental group will receive 1 gram of tranexamic acid, which will be stored at room temperature. The medication will be prepared in a 20-mL syringe at the patient'
s ward and transported with the patient on the day of surgery. It will be administered intravenously over a period of 5 minutes following the induction of anesthesia.,The control group will receive 20
s ward and transported with the patient on the day of surgery. It will be administered intravenously following the induction of anesthesia
Experimental Drug,Placebo Comparator Drug
Sponsors
Rajavithi Hospital
Eligibility
Sex/Gender
Female
Age
18 Years to 50 Years
Inclusion criteria
Inclusion criteria: 1. Age 18 to 50 year 2. Disease severity classified as ASRM Stage I to Stage IV 3. No prior use of hormonal therapy or GnRH agonists within 3 months prior to surgery 4. American Society of Anesthesiologists : ASA physical status classification I and II 5. Ability to speak and comprehend the Thai language fluently 6. Willingness to participate and provide informed consent for the study
Exclusion criteria
Exclusion criteria: 1. Current pregnancy 2. Planned concurrent other surgical procedures during the same operative session. 3. Contraindications to tranexamic acid, including severe drug hypersensitivity. 4. Intraoperative conversion from laparoscopic surgery to open laparotomy. 5. Chronic kidney disease (CKD). 6. Current use of medications affecting blood loss, including herbal supplements, aspirin, warfarin, or other anticoagulants and antiplatelet agents. 7. History or presence of thromboembolic disorders. 8. Coagulopathy or presence of bleeding disorders. 9. Cognitive impairment or intellectual disability.
Design outcomes
Primary
| Measure | Time frame |
|---|---|
| Hemoglobin level 24 hours Complete blood count | — |
Secondary
| Measure | Time frame |
|---|---|
| Estimate blood loss Intraoperative Intraoperative blood loss,Change of hemoglobin level 24 hours Complete blood count,Blood transfusion needed 24 hours Blood transfusion,Electrocautery use score Intraoperative Electrocautery use score from 1-3,Time of hospitalization Intraoperative Time | — |
Countries
Thailand
Contacts
Public ContactTanaree Chatyingmongkol
Rajavithi hospital
Outcome results
None listed